The CEO Roundtable on Cancer has elected Joaquin Duato of Johnson & Johnson to its Board of Directors.
The CEO Roundtable on Cancer, a nonprofit organization of executives, was founded by former President George H.W. Bush in 2001 with a mandate to bring bold and imaginative solutions to cancer treatment and prevention. Chaired by Robert Bradway, President and CEO of Amgen, the CEO Roundtable on Cancer has led efforts in both global health and research innovation.
“I am pleased to welcome Joaquin Duato to the CEO Roundtable on CancerBoard of Directors,” said CEO Roundtable on Cancer Chairman and Amgen CEO Robert Bradway. “I look forward to working with Joaquin and to the continued progress we will make advancing access, research and prevention efforts.”
Duato, currently the Executive Vice President and Worldwide Chairman, Pharmaceuticals, at Johnson & Johnson, is a respected industry leader and also the Chairman-Elect of the Pharmaceutical Research and Manufacturers of America (PhRMA).
“Recently the pharmaceutical industry has led the way in conquering the health challenges of the 20th century,” said Duato. “Cancer is the next frontier and I am proud to have the privilege of serving on the Board of the CEO Roundtable on Cancer during this pivotal time.”
The CEO Roundtable on Cancer’s first initiative, the CEO Cancer Gold Standard™ workplace accreditation program, recognizes employers’ efforts to build a culture of wellness by promoting healthy lifestyle choices, encouraging cancer screening and promoting access to quality cancer treatment. Johnson & Johnson is one of six inaugural organizations which first earned Gold Standard status in 2006, and the company is among only four organizations that are globally accredited. The CEO Roundtable on Cancer is sharing this employer-led cancer prevention and wellness promotion program in China with government, industry and international cancer experts to bring the benefits of the Gold Standard to the world’s most populated country. Today, nearly 200 private, nonprofit and government employers in a wide range of industries have earned Gold Standard accreditation.
In 2012, the CEO Roundtable on Cancer established Project Data Sphere, LLC, an independent not-for-profit initiative that created a clinical trial data sharing platform (www.ProjectDataSphere.org) to advance oncology research. Johnson & Johnson was among the pioneering data providers to this digital library-laboratory. More than 1,300 authorized researchers work on the Project Data Sphere®platform that provides free access to clinical trial datasets across core cancer tumor types. To realize the full potential of these data, SAS, a leader in data and health analytics, which developed and hosts the website, provides SAS Analytic Tools free of charge to all registered users.
A growing compendium of more than a dozen peer-reviewed publications have resulted from researchers having the access to patient level clinical trial data via the Project Data Sphere repository. In addition to Johnson & Johnson, other data providers include: Amgen, AstraZeneca, Bayer, Celgene, EMD Serono, Eli Lilly, Memorial Sloan Kettering Cancer Center, Pfizer, Synta, Sanofi and The Alliance for Clinical Trials in Oncology, one of the five U.S. network groups of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN).